Alberto Espay, MD, MSc, University of Cincinnati, Cincinnati, OH, explains the importance of biological subtyping for future successes in personalized treatments for neurodegenerative diseases. The current diagnosis of neurodegenerative diseases considers the symptoms of the disease but not the underlying biological processes. Understanding the biological cause of the disease will allow for treatment with therapies that target the specific process, meaning increased efficacy of treatments. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Dr. Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Neuroderm, Amneal, Acadia, Avion Pharmaceuticals, Acorda, Kyowa Kirin, Sunovion, Supernus (formerly, USWorldMeds), and Herantis Pharma; personal honoraria for speakership for Avion, Amneal, and Supernus; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He cofounded REGAIN Therapeutics and is co-inventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies.” He serves on the editorial boards of the Journal of Parkinson’s Disease, Journal of Alzheimer’s Disease, European Journal of Neurology, Movement Disorders Clinical Practice, and JAMA Neurology.